Hepatitis Forums
Hepatitis C Main Forums => Considering Hepatitis C Treatment => Topic started by: PattheCat on September 16, 2017, 07:33:54 am
-
I've relapsed following 12 weeks of Harvoni and, prior to that, relapsed following 12 weeks of Sovaldi/Interferon/Ribavirin.
I now have the opportunity to participate in a clinical trial with 12 weeks of Mavyret. My concern is that the FDA-approved treatment for NS5A inhibitor-experienced patients (me) is 16 weeks of Mavyret. In previous trials, the success rate advertised for NS5A-experienced patients with a 16-week treatment is approximately 94%. The company does not have available data for 12-week treatments of the same population. My concern is that if the 12-week treatment (presumably sub-optimal) is unsuccessful, the treatment may do more harm than good. My insurance company currently does not cover treatment with Mavyret. Any advice?
-
Can you get approved for Vosevi? It worked for me after relapsing after 24 weeks on Harvoni and prior to that 24 week clinical trial of 2 other DAAs.
-
Can you get approved for Vosevi? It worked for me after relapsing after 24 weeks on Harvoni and prior to that 24 week clinical trial of 2 other DAAs.
-
Thanks northfork!
Great news that you were cured earlier this year. Congratulations!
My insurance covers neither Mavyret nor Vocevi. I may just have to wait.
-
I've been told that in about a year's time a generic mavyret will be available. Maybe wait then take it with another DAA and ribavarin which are also available in generic form. Lots cheaper and do 3 months as you said. Could be your last chance to knock it on the head
-
Thanks PCTree!
I actually got approved for 12 weeks of Vosevi. Just finished the regimen and waiting for blood work in April.
-
Hope it worked for you like it did for me!
-
I've relapsed following 12 weeks of Harvoni and, prior to that, relapsed following 12 weeks of Sovaldi/Interferon/Ribavirin.
I now have the opportunity to participate in a clinical trial with 12 weeks of Mavyret. My concern is that the FDA-approved treatment for NS5A inhibitor-experienced patients (me) is 16 weeks of Mavyret. In previous trials, the success rate advertised for NS5A-experienced patients with a 16-week treatment is approximately 94%. The company does not have available data for 12-week treatments of the same population. My concern is that if the 12-week treatment (presumably sub-optimal) is unsuccessful, the treatment may do more harm than good. My insurance company currently does not cover treatment with Mavyret. Any advice?
I was diagnosed with Hep c back in 2004 viral load 1,519,000 as of last week. I tried to get the insurance company to pay for Harvoni, they denied me then the doctor wrote a script for Mavyret and the insurance company denied me twice. I contacted mavyret directly and asked for the paperwork for the patient assistance program I just got approved for the medication 2 weeks ago at at mo cost. I recommend that you call them directly and ask about that program. Honestly I am truly blessed that they’re willing to pay for it when no one else would help me .